Abstract:Circulation Research, Ahead of Print. BACKGROUND:Chronic overconsumption of lipids followed by their excessive accumulation in the heart leads to cardiomyopathy. The cause of lipid-induced cardiomyopathy involves a pivotal role for the proton-pump vacuolar-type H+-ATPase (v-ATPase), which acidifies endosomes, and for lipid-transporter CD36, which is stored in acidified endosomes. During lipid overexposure, an increased influx of lipids into cardiomyocytes is sensed by v-ATPase, which then disassembles, causing endosomal de-acidification and expulsion of stored CD36 from the endosomes toward the sarcolemma. Once at the sarcolemma, CD36 not only increases lipid uptake but also interacts with inflammatory receptor TLR4 (Toll-like receptor 4), together resulting in lipid-induced insulin resistance, inflammation, fibrosis, and cardiac dysfunction. Strategies inducing v-ATPase reassembly, that is, to achieve CD36 reinternalization, may correct these maladaptive alterations. For this, we used NAD+-precursor nicotinamide mononucleotide (NMN), inducing v-ATPase reassembly by stimulating glycolytic enzymes to bind to v-ATPase.METHODS:Rats/mice on cardiomyopathy-inducing high-fat diets were supplemented with NMN and for comparison with a cocktail of lysine/leucine/arginine (mTORC1-mediated v-ATPase reassembly). We used the following methods: RNA sequencing, mRNA/protein expression analysis, immunofluorescence microscopy, (co)immunoprecipitation/proximity ligation assay (v-ATPase assembly), myocellular uptake of [3H]chloroquine (endosomal pH), and [14C]palmitate, targeted lipidomics, and echocardiography. To confirm the involvement of v-ATPase in the beneficial effects of both supplementations, mTORC1/v-ATPase inhibitors (rapamycin/bafilomycin A1) were administered. Additionally, 2 heart-specific v-ATPase-knockout mouse models (subunits V1G1/V0d2) were subjected to these measurements. Mechanisms were confirmed in pharmacologically/genetically manipulated cardiomyocyte models of lipid overload.RESULTS:NMN successfully preserved endosomal acidification during myocardial lipid overload by maintaining v-ATPase activity and subsequently prevented CD36-mediated lipid accumulation, CD36-TLR4 interaction toward inflammation, fibrosis, cardiac dysfunction, and whole-body insulin resistance. Lipidomics revealed C18:1-enriched diacylglycerols as lipid class prominently increased by high-fat diet and subsequently reversed/preserved by lysine/leucine/arginine/NMN treatment. Studies with mTORC1/v-ATPase inhibitors and heart-specific v-ATPase-KO mice further confirmed the pivotal roles of v-ATPase in these beneficial actions.CONCLUSION:NMN preserves heart function during lipid overload by preventing v-ATPase disassembly.

Mechanisms Underlying the Therapeutic Effects of Nicotinamide Mononucleotide in Treating High-Fat Diet-induced Hypertrophic Cardiomyopathy based on GEO Datasets, Network Pharmacology, and Molecular Docking

1-Deoxynojirimycin Promotes Cardiac Function and Rescues Mitochondrial Cristae in Mitochondrial Hypertrophic Cardiomyopathy.

Nicotinamide Mononucleotide: Research Process in Cardiovascular Diseases

Glycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36–TLR4 Axis

Mining Potential Drug Targets and Constructing Diagnostic Models for Heart Failure Based on Mirna-Mrna Networks

Nicotinamide Mononucleotide Protects Against High-Fat-diet-induced Atherosclerosis in Mice and Dampens Aortic Inflammation and Oxidative Stress

Nicotinamide mononucleotide: An emerging nutraceutical against cardiac aging?

Abstract 13420: Nicorandil Suppresses Mitochondria-Associated Ferroptosis to Attenuates Cardiac Microvascular Disorder in Diabetes: Role of Mitochondria-Localized AMPKα1

Short-term Administration of Nicotinamide Mononucleotide Preserves Cardiac Mitochondrial Homeostasis and Prevents Heart Failure.

Nicotinamide mononucleotide alters body composition and ameliorates metabolic disorders induced by a high-fat diet

Alleviation of hepatic insulin resistance and steatosis with NMN via improving endoplasmic reticulum–Mitochondria miscommunication in the liver of HFD mice

Identification of ATRNL1 and WNT9A as novel key genes and drug candidates in hypertrophic cardiomyopathy: integrative bioinformatics and experimental validation

Nicotinamide Mononucleotide (NMN) Works in Type 2 Diabetes through Unexpected Effects in Adipose Tissue, Not by Mitochondrial Biogenesis

Nicotinamide Mononucleotide Inhibits Hepatic Stellate Cell Activation to Prevent Liver Fibrosis Via Promoting PGE2 Degradation

Nicotinamide Mononucleotide (NMN) Ameliorates Free Fatty Acid-Induced Pancreatic β-Cell Dysfunction via the NAD+/AMPK/SIRT1/HIF-1α Pathway

Nicotinamide Mononucleotide Attenuates Isoproterenol-Induced Cardiac Fibrosis by Regulating Oxidative Stress and Smad3 Acetylation.

Nicotinamide Mononucleotide in the Context of Myocardiocyte Longevity

Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy

Recent advance in role of nicotinamide mononucleotide in central nervous system diseases

EXERCISE-INDUCED BENEFITS ON GLUCOSE HANDLING IN A MODEL OF DIET-INDUCED OBESITY ARE REDUCED BY CONCURRENT NICOTINAMIDE MONONUCLEOTIDE

Nicotinamide mononucleotide (NMN) alleviates the poly(I:C)-induced inflammatory response in human primary cell cultures